I've been reading up on the dialysis bundle and how MD's charge Medicare for drugs they prescribe .
My understanding so far
Say OLC is kept out of the dialysis bundle and charge $1,000 a month for their OLC .
It would be a tier 5 drug so patient copay would be roughly 25% ( $250 ) a month with Medicare paying $750 a mth .
Co then offers a $200 coupon to the patient ... Patient then only pays $50 ....BUT ... Medicare is still paying the remainder $750 a mth
This only works if the new oral pho binders are kept out of the dialysis bundle . The bundle is a fixed payment dialysis centers need to operate in ...paid per patient dialysis . Theres no room there for new Brand drugs ....within the existing dialysis bundle
So ...thats the play ... out of the bundle or bust
JMO
Kiwi
PS Great Point Partners disclosed a 9.9 % stake recently ...Is this a new stake ...Anyway you can find out
Recent UNCY News
- Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 • GlobeNewswire Inc. • 10/28/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 • GlobeNewswire Inc. • 10/16/2024 08:35:00 PM
- Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 • GlobeNewswire Inc. • 10/14/2024 11:03:00 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/11/2024 08:02:13 PM
- Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers • GlobeNewswire Inc. • 10/09/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 • GlobeNewswire Inc. • 09/24/2024 11:03:00 AM
- Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 • GlobeNewswire Inc. • 09/16/2024 11:03:00 AM
- Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 11:03:00 AM
- Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis • GlobeNewswire Inc. • 09/03/2024 11:03:00 AM
- Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 • GlobeNewswire Inc. • 08/26/2024 11:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:15:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:11:52 PM
- Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 11:10:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:05:53 AM
- Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO) • GlobeNewswire Inc. • 07/17/2024 11:03:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/17/2024 04:15:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/16/2024 02:31:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:15:11 PM
- Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • GlobeNewswire Inc. • 07/11/2024 11:03:00 AM
- Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 07/10/2024 11:03:00 AM
- Unicycive Therapeutics Joins Russell Microcap® Index • GlobeNewswire Inc. • 07/01/2024 11:03:00 AM
- Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial • GlobeNewswire Inc. • 06/25/2024 11:30:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM